-
- A Perri and R Fumagalli.
- Università degli Studi Milano Bicocca, Dipartimento di Medicina Sperimentale, Azienda Ospedaliera San Gerardo di Monza, Monza, Italy.
- Transplant. Proc. 2008 May 1;40(4):1207-11.
AbstractSevere sepsis in transplant recipients results in an extremely high morbidity mortality rate. Microvascular alterations play an important role in the development of sepsis-induced organ dysfunction. Therefore, addition to standard treatment, which we divide into prophylaxis, preemptive therapy, and therapy, activated protein C (or Drotrecogin Alpha Activated [DAA]) represents a radically new approach for these patients. Herein we have reported the first trials evaluating the use of DAA in transplant recipients experiencing sepsis. Comparable trials in humans are still not available for the other coagulation, inhibitor antithrombin. We also report clinical trials discussing whether hyperimmune products reduce the infection rate during myelosuppression, but further trials are requested for the feasible evaluation of these products.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*,_underline_or**bold**. - Superscript can be denoted by
<sup>text</sup>and subscript<sub>text</sub>. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3., hyphens-or asterisks*. - Links can be included with:
[my link to pubmed](http://pubmed.com) - Images can be included with:
 - For footnotes use
[^1](This is a footnote.)inline. - Or use an inline reference
[^1]to refer to a longer footnote elseweher in the document[^1]: This is a long footnote..